A multicentre, randomised, double-blind, placebo-controlled trial to evaluate intravenous infusion of salbutamol versus saline for 28-day mortality in patients with acute respiratory distress syndrome

Conditions

Acute respiratory distress syndrome Respiratory Respiratory distress syndrome

Gates S, Perkins GD, Lamb SE, Kelly C, Thickett DR, Young JD, McAuley DF, Snaith C, McCabe C, Hulme CT, Gao Smith F.

2013-09-0130 citations

Effect of intravenous β-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial.

Gao Smith F, Perkins GD, Gates S, Young D, McAuley DF, Tunnicliffe W, Khan Z, Lamb SE, BALTI-2 study investigators.

2011-12-11219 citations

10.1016/s0140-6736(11)61623-1

Beta Agonist Lung Injury TrIal-2 (BALTI-2) trial protocol: a randomised, double-blind, placebo-controlled of intravenous infusion of salbutamol in the acute respiratory distress syndrome.

Perkins GD, Gates S, Lamb SE, McCabe C, Young D, Gao F.

2011-05-0914 citations

10.1186/1745-6215-12-113

Interventions

Salbutamol or placebo will be administered through a dedicated intravenous line for seven days

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: On day 1 following intensive care unit (ICU) admission, the primary caring ICU clinician should consider all adult patients (age =18 years) with severe hypoxaemic respiratory failure (PaO2/FiO2) =26.7 kPa to be eligible for inclusion in the trial

Exclusion criteria

Exclusion criteria: 1. Pregnancy 2. Cardiogenic pulmonary oedema (confirmed by medical history and chest x-ray) 3. Severe obstructive airway disease requiring nebulised or intravenous (IV) beta 2-agonists 4. Treatment with beta 2-blockers =48 hours 5. Brain stem death 6. Treatment withdrawal =24 hours, which indicates any interventions (including a trial) would be considered inappropriate 7. Refusing consent or patients in whom relatives refuse assent 8. Enrolled in another interventional clinical trial in the last 28 days

Design outcomes

Primary

Measure	Time frame
Mortality 28 days after randomisation	—

Secondary

Measure	Time frame
1. Number of ventilator-free days 2. Mortality at (first) discharge from ICU 3. Mortality at discharge from hospital 4. Mortality at 12 months post randomisation 5. ICU length of stay 6. Hospital length of stay 7. Disability and quality of life at 12 months after randomisation	—

Countries

United Kingdom

Outcome results

None listed